Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male and female patients with type 2 diabetes and with glomerular filtration rate (GFR) \<30 ml/min, who are not on chronic dialysis.~* Insufficient glycemic control (hemoglobin A1c (HbA1c) between 7.0% and 10.0%)~* Age 18 or over and not older than 80 years~Exclusion criteria:~* Treatment with any other anti diabetic drug other than insulin and/or sulphonylurea within 3 months prior to informed consent~* Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent~* Unstable or acute congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 1356 (Type: EXPERIMENTAL): patient to receive a tablet containing BI 1356 once daily
- placebo (Type: PLACEBO_COMPARATOR): patient to receive a tablet identical to BI 1356 once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).